drugset / Trial / NCT02171442

Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers

NCT02171442

Phase 1 Completed 10 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study were to investigate the metabolism and pharmacokinetics of BIBR 1048 MS and BIBR 953 ZW in man.

Timeline

Start
2002-04
Primary completion
2002-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran Unknown 2.8 mbq Intravenous
Subject Dabigatran Unknown 5 mg Intravenous
Comparator Dabigatran etexilate Unknown 2.8 mbq Oral
Comparator Dabigatran etexilate Unknown 200 mg Oral

Indications

No indication recorded.